(USA Today) – The U.S. Food and Drug Administration on Wednesday approved Amgen Inc.’s heart-failure treatment Corlanor, which had been designated for priority review in August. The drug is an oral medication intended to regulate heart rate and reduce the risk of hospitalization for worsening heart failure in patients with stable, chronic heart failure caused by a […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.